CEFETAMET PIVOXIL IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN

CEFETAMET PIVOXIL IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN

Author Syrogiannopoulos, G. A. Google Scholar
Chibante, AMD Google Scholar
Gatzola, M. Google Scholar
Toporovski, J. Google Scholar
Madrid, B. Google Scholar
Farhat, Calil Kairalla Autor UNIFESP Google Scholar
Fall, M. Google Scholar
Burgio, G. R. Google Scholar
Likitnukul, S. Google Scholar
Kissling, M. Google Scholar
Institution F HOFFMANN LA ROCHE & CO LTD
UNIV HOSP PATRAS
HOSP GAFFREE & GUINLE
HOSP AHEPA
Universidade Federal de São Paulo (UNIFESP)
PHILIPPINES GEN HOSP
POLICLIN SAN MATTEO
CHULALONGKORN HOSP
HOP LE DANTEC
Abstract The efficacy and safety of cefetamet pivoxil in the treatment of community-acquired pneumonia in children were assessed in an open, randomised, comparative multicentre study in which 260 children (in- and outpatients) with either bacterial pneumonia (n = 170) or bronchopneumonia (n = 90) were enrolled. Cefetamet pivoxil, an oral third generation cephalosporin, was administered to 85 children at a dosage of 10 mg/kg twice daily, the recommended therapeutic dosage, and to 94 children at a dosage of 20 mg/kg twice daily. Cefaclor was administered to 81 children at a dosage of 10 mg/kg three times daily. The duration of treatment was 7 days. Assessments were performed on days 0, 3, 7 and 14 after initiation of treatment. Clinical signs and symptoms began to improve soon after the start of treatment, and continued to improve in all 3 treatment groups. The therapeutic outcome was considered successful in 80 of the 81 assessable patients receiving cefetamet pivoxil 10 mg/kg twice daily (98.8%), in 79 of the 81 assessable patients receiving cefetamet pivoxil 20 mg/kg twice daily (97.6%), and in 71 of the 75 assessable patients receiving cefaclor 10 mg/kg three times daily (94.7%). The differences in outcome between the 3 groups were not statistically significant. Adverse events were of gastrointestinal origin (mainly diarrhoea, nausea, and/or vomiting), and occurred with similar frequencies in the groups treated with cefetamet pivoxil 10 mg/kg twice daily and cefaclor 10 mg/kg three times daily.Cefetamet pivoxil administered at the standard dosage of 10 mg/kg twice daily was effective and well tolerated in children with bacterial pneumonia or bronchopneumonia. The twice-daily cefetamet pivoxil dose schedule compares favourably with the well-established cefaclor 3-times-daily regimen and may result in improved compliance.
Language English
Date 1994-07-01
Published in Drug Investigation. Auckland: Adis International Ltd, v. 8, n. 1, p. 31-37, 1994.
ISSN 0114-2402 (Sherpa/Romeo, impact factor)
Publisher Adis International Ltd
Extent 31-37
Origin https://doi.org/10.1007/BF03257424
Access rights Closed access
Type Article
Web of Science ID WOS:A1994NY65700004
URI http://repositorio.unifesp.br/11600/43499

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account